Trial Profile
A Long Term Off-treatment Follow-Up Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients in China Previously Treated With Daclatasvir-Based Regimens
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jun 2020
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 18 Dec 2019 Status changed from recruiting to completed.
- 12 Dec 2017 New trial record